Bicycle Therapeutics PLC Form 4 insider transactions

Michael Skynner, Chief Technology Officer of Bicycle Therapeutics, acquired shares through a restricted stock unit vesting and sold shares to cover tax obligations.

Michael Hannay, Chief Product and Supply Chain Officer at Bicycle Therapeutics, reports the acquisition of restricted stock units, the sale of shares to cover tax obligations, and the grant of stock options.

CEO Kevin Lee reports acquisition of restricted stock units (RSUs), sales to cover tax obligations, and grants a power of attorney for SEC filings.

Director Gregory Winter of Bicycle Therapeutics PLC reports acquisition of stock options and restricted stock units.

Director Stephen Sands reports acquisition of restricted stock units and stock options in Bicycle Therapeutics PLC.

Director Richard N. Kender reports the acquisition of restricted stock units and stock options in Bicycle Therapeutics PLC.

Director Jose-Carlos Gutierrez-Ramos reports the acquisition of stock options and restricted stock units (RSUs) in Bicycle Therapeutics PLC.

Director Janice Bourque reports acquisition of restricted stock units and stock options in Bicycle Therapeutics PLC.

Baker Bros. Advisors LP and related entities report the acquisition of restricted stock units and share options in Bicycle Therapeutics PLC, reflecting indirect beneficial ownership.

Baker Bros. Advisors LP and related entities have increased their holdings in Bicycle Therapeutics PLC through a series of purchases of American Depositary Shares (ADS) on December 13th and 16th, 2024.

Bicycle Therapeutics' Chief Accounting Officer, Travis Alvin Thompson, engaged in multiple stock transactions, including both acquisitions and disposals, under a pre-arranged 10b5-1 trading plan.

CEO Kevin Lee sold 3,212 ordinary shares of Bicycle Therapeutics PLC to cover statutory tax withholding obligations related to the vesting and settlement of Restricted Stock Units (RSUs).

Michael Charles Ferguson Hannay, Chief Product & Supply Chain Officer of Bicycle Therapeutics PLC, sold shares to cover tax withholding obligations related to vested RSUs.

Michael Skynner, Chief Technology Officer of Bicycle Therapeutics PLC, sold 972 ordinary shares to cover tax withholding obligations related to the vesting and settlement of Restricted Stock Units (RSUs).

Alistair Milnes, COO of Bicycle Therapeutics PLC, sold 972 ordinary shares to cover tax withholding obligations related to the vesting and settlement of Restricted Stock Units (RSUs).

Nigel Crockett, Chief Business Officer of Bicycle Therapeutics PLC, sold 972 ordinary shares to cover tax withholding obligations related to the vesting and settlement of Restricted Stock Units (RSUs).

Travis Alvin Thompson, Chief Accounting Officer of Bicycle Therapeutics PLC, sold 153 ordinary shares to cover tax withholding obligations related to the vesting and settlement of Restricted Stock Units (RSUs).

Michael Charles Ferguson Hannay, Chief Product & Supply Chain Officer of Bicycle Therapeutics PLC, sold 246 ordinary shares to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).

Michael Skynner, Chief Technology Officer of Bicycle Therapeutics PLC, sold 967 ordinary shares to cover tax withholding obligations related to the vesting and settlement of Restricted Stock Units (RSUs).

Travis Alvin Thompson, Chief Accounting Officer of Bicycle Therapeutics PLC, sold 148 ordinary shares to cover tax withholding obligations related to the vesting and settlement of RSUs.

Nigel Crockett, Chief Business Officer of Bicycle Therapeutics PLC, sold 967 ordinary shares to cover tax withholding obligations related to the vesting and settlement of RSUs.

Nicholas Keen, Chief Scientific Officer of Bicycle Therapeutics PLC, sold 779 ordinary shares to cover tax withholding obligations related to the vesting and settlement of RSUs.

Bicycle Therapeutics CEO Kevin Lee sold 3,194 ordinary shares to cover statutory tax withholding obligations related to the vesting and settlement of Restricted Stock Units (RSUs).

Alistair Milnes, Chief Operating Officer of Bicycle Therapeutics PLC, sold 967 ordinary shares to cover tax withholding obligations related to the vesting and settlement of RSUs on July 3, 2024.

Baker Bros. Advisors LP converted non-voting ordinary shares of Bicycle Therapeutics PLC into ordinary shares in the form of American Depositary Shares (ADS) on June 17, 2024.

Baker Bros. Advisors and affiliated entities increased their holdings in Bicycle Therapeutics through a private placement of non-voting ordinary shares.

Baker Bros. Advisors and related entities report changes in beneficial ownership of Bicycle Therapeutics plc stock and options due to director Felix J. Baker's equity grants.

Michael Charles Ferguson Hannay, Chief Product & Supply Chain Officer of Bicycle Therapeutics plc, sold 257 ordinary shares to cover tax withholding obligations related to the vesting and settlement of RSUs.

CEO of Bicycle Therapeutics, Kevin Lee, sold 3,158 ordinary shares to cover tax withholding obligations related to the vesting and settlement of Restricted Stock Units (RSUs).

Michael Skynner, Chief Technology Officer of Bicycle Therapeutics plc, sold 955 ordinary shares to cover tax withholding obligations related to the vesting and settlement of RSUs.